Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Prockop

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood|October 26, 2019
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALLKevin J Curran, Steven P Margossian, Nancy A Kernan, et al.
Blood|January 21, 2022
Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplantOriana Miltiadous, Nicholas R Waters, Hana Andrlová, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2016
Ex Vivo CD34<sup>+</sup>-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment ResponsePere Barba, Patrick Hilden, Sean M Devlin, et al.
Nature Medicine|January 4, 2022
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trialFarid Boulad, Aurelio Maggio, Xiuyan Wang, et al.
The Journal of Clinical Investigation|November 6, 2019
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantationSusan Prockop, Ekaterina Doubrovina, Stephanie Suser, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)Christopher C Dvorak, Elie Haddad, Rebecca H Buckley, et al.
Blood Advances|July 29, 2024
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunityTim Bognàr, Moises Garcia-Rosa, Arief Lalmohamed, et al.
The Journal of Allergy and Clinical Immunology|January 30, 2024
Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A  Primary Immune Deficiency Treatment Consortium studyEyal Grunebaum, Danielle E Arnold, Brent Logan, et al.
Frontiers in Immunology|October 19, 2017
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood|October 26, 2019
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALLKevin J Curran, Steven P Margossian, Nancy A Kernan, et al.
Blood|January 21, 2022
Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplantOriana Miltiadous, Nicholas R Waters, Hana Andrlová, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2016
Ex Vivo CD34<sup>+</sup>-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment ResponsePere Barba, Patrick Hilden, Sean M Devlin, et al.
Nature Medicine|January 4, 2022
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trialFarid Boulad, Aurelio Maggio, Xiuyan Wang, et al.
The Journal of Clinical Investigation|November 6, 2019
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantationSusan Prockop, Ekaterina Doubrovina, Stephanie Suser, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)Christopher C Dvorak, Elie Haddad, Rebecca H Buckley, et al.
Blood Advances|July 29, 2024
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunityTim Bognàr, Moises Garcia-Rosa, Arief Lalmohamed, et al.
The Journal of Allergy and Clinical Immunology|January 30, 2024
Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A  Primary Immune Deficiency Treatment Consortium studyEyal Grunebaum, Danielle E Arnold, Brent Logan, et al.
Frontiers in Immunology|October 19, 2017
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Pageof 7